Literature DB >> 11350856

Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy.

P H Goossens1, R J Verburg, F C Breedveld.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11350856      PMCID： PMC1753667          DOI： 10.1136/ard.60.6.637

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  17 in total

Review 1.  Behçet's disease: from Hippocrates to the third millennium.

Authors:  D H Verity; G R Wallace; R W Vaughan; M R Stanford
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

2.  Neurological symptoms of Adamantiades-Behçet's syndrome.

Authors:  J M S Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-08       Impact factor: 10.154

3.  Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis.

Authors:  Harald Mangge; Bernd Heinzl; Hans-Michael Grubbauer; Yosuf El-Shabrawi; Konrad Schauenstein
Journal:  Rheumatol Int       Date:  2003-04-10       Impact factor: 2.631

Review 4.  Behçet's disease: a new target for anti-tumour necrosis factor treatment.

Authors:  P P Sfikakis
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

5.  Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Behçet's disease.

Authors:  Aşkin Ateş; Gülay Kinikli; Nurşen Düzgün; Murat Duman
Journal:  Rheumatol Int       Date:  2005-05-05       Impact factor: 2.631

Review 6.  Mucocutaneous lesions of Behcet's disease.

Authors:  Erkan Alpsoy; Christos Constantin Zouboulis; George Edward Ehrlich
Journal:  Yonsei Med J       Date:  2007-08-31       Impact factor: 2.759

7.  Etanercept therapy in Behçet's disease. The tight control strategy in refractory disease.

Authors:  R H A Mohammed
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

8.  Successful treatment with adalimumab in a patient with coexisting Behçet's disease and ankylosing spondylitis.

Authors:  Necmettin Yildiz; Hakan Alkan; Fusun Ardic; Oya Topuz
Journal:  Rheumatol Int       Date:  2009-08-25       Impact factor: 2.631

9.  One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs.

Authors:  Annarita Giardina; Angelo Ferrante; Francesco Ciccia; Maria Vadalà; Ennio Giardina; Giovanni Triolo
Journal:  Rheumatol Int       Date:  2009-10-27       Impact factor: 2.631

10.  Blocking lymphotoxin-beta receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression and leucocyte margination in chronic DSS-induced colitis.

Authors:  P Stopfer; F Obermeier; N Dunger; W Falk; S Farkas; M Janotta; A Möller; D N Männel; T Hehlgans
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.